news.google.com
Roivant’s road to a potential blockbuster begins with Lisraya FDA approval - Endpoints NewsRoivant’s road to a potential blockbuster begins with Lisraya FDA approval Endpoints News...news.google.com
Pharma’s legal battle over Medicare negotiations reaches ‘dead end’ - Endpoints NewsPharma’s legal battle over Medicare negotiations reaches ‘dead end’ Endpoints News...news.google.com
Q&A: Akeso CEO spells out why she thinks its biliary tract cancer data are a big deal - Endpoints NewsQ&A: Akeso CEO spells out why she thinks its biliary tract cancer data are a big deal Endpoints News...news.google.com
Tezepelumab Meets Co-Primary Endpoints in Phase 3 EoE Trial - HCPLiveTezepelumab Meets Co-Primary Endpoints in Phase 3 EoE Trial HCPLive...news.google.com
Lilly’s move to hide Phase 1 pipeline draws mixed reviews - Endpoints NewsLilly’s move to hide Phase 1 pipeline draws mixed reviews Endpoints News...news.google.com
Moderna’s $2B offering; AstraZeneca-Amgen and Biokin chalk up Phase 3 wins - Endpoints NewsModerna’s $2B offering; AstraZeneca-Amgen and Biokin chalk up Phase 3 wins Endpoints News...news.google.com
RayzeBio’s $173M radiopharma plan; Lonza creates commercial chief position - Endpoints NewsRayzeBio’s $173M radiopharma plan; Lonza creates commercial chief position Endpoints News...news.google.com
Exclusive: Metriport raises $26M to help doctors retrieve patient data - Endpoints NewsExclusive: Metriport raises $26M to help doctors retrieve patient data Endpoints News...news.google.com
AstraZeneca meets all endpoints in late-stage trials of Tezspire - medwatch.comAstraZeneca meets all endpoints in late-stage trials of Tezspire medwatch.com...news.google.com
Tezspire Hits Both Primary Endpoints in Phase 3 Eosinophilic Esophagitis Trial - The Clinical Trial VanguardTezspire Hits Both Primary Endpoints in Phase 3 Eosinophilic Esophagitis Trial The Clinical Trial Vanguard...news.google.com
2026 Endpoints 11 - Massachusetts Biotechnology Council2026 Endpoints 11 Massachusetts Biotechnology Council...news.google.com
Exclusive: Can AI chop clinical trial timelines in half? Faro raises $37M to find out - Endpoints NewsExclusive: Can AI chop clinical trial timelines in half? Faro raises $37M to find out Endpoints News...news.google.com
ARCH and Population Health join China blitz with Haisco deal - Endpoints NewsARCH and Population Health join China blitz with Haisco deal Endpoints News...news.google.com
Bristol Myers ends deal with Cellares, cell therapy manufacturer to reorg - Endpoints NewsBristol Myers ends deal with Cellares, cell therapy manufacturer to reorg Endpoints News...news.google.com
Exclusive: Bausch + Lomb plans Phase 3 trial for dry eye drop, despite missing mid-stage goal - Endpoints NewsExclusive: Bausch + Lomb plans Phase 3 trial for dry eye drop, despite missing mid-stage goal Endpoints News...news.google.com
DC judge rejects Merck’s IRA case more than three years after it was filed - Endpoints NewsDC judge rejects Merck’s IRA case more than three years after it was filed Endpoints News...news.google.com
TwinStrand wins patent case; GSK’s hepatitis B drug approved in Japan - Endpoints NewsTwinStrand wins patent case; GSK’s hepatitis B drug approved in Japan Endpoints News...news.google.com
News on AstraZeneca, Cytokinetics, Novartis and more — what to look out for at ESC 2026 - Endpoints NewsNews on AstraZeneca, Cytokinetics, Novartis and more — what to look out for at ESC 2026 Endpoints News...news.google.com
BE BOLD Efficacy and Safety Data: Comparing Bimekizumab and Risankizumab on Joint-Centric Endpoints - Managed Healthcare ExecutiveBE BOLD Efficacy and Safety Data: Comparing Bimekizumab and Risankizumab on Joint-Centric Endpoints Managed Healthcare Executive...news.google.com
Roche bets up to $2.3B on Hanmi’s early-stage muscle-building obesity asset - Endpoints NewsRoche bets up to $2.3B on Hanmi’s early-stage muscle-building obesity asset Endpoints News...